We evaluated the clinical significance of simultaneous transurethral resection of bladder tumor (TURB) and the prostate (TURP) in patients who have superficial bladder cancer with bladder outlet obstruction. Materials and Methods: Between April 1997 to April 2006, 213 patients with superficial bladder cancer were included in this study. The patients were treated with TURB only (n=107, Group I) or TURB with TURP (n=106, Group II). Bladder cancer recurrence was observed by performing cystoscopy and urine cytology. Uroflowmetry was performed three months after surgery. Results: There were no significant differences in age, the tumor size or the number of tumors between groups I and II. There was no evidence of cancer implantation where TURP was applied. The recurrence rate of group II was significantly lower than that of group I (p=0.044), and the time to recurrence was longer for group II than for group I (p=0.026). There was no significant difference in the progression rate between the two groups (p=0.788). Three months after surgery, the mean residual urine volume was lower for group II (7.9ml) than that for group I (21.7ml). Conclusions: For superficial bladder cancer patients with bladder outlet obstruction, simultaneous TURB and TURP may help reduce the bladder cancer recurrence rate and delay the time to recurrence without the risk of cancer implantation at the site where TURP is applied. (Korean J Urol 2008;49:791-796) 서 론 방광이행상피세포암은 70%가 표재성이며 경요도방광암 절제술 (transurethral resection of bladder tumor; TURB)을 시 행한 후 방광 내 Bacillus Calmette-Guerin (BCG) 혹은 항암 약물투여 등과 같은 보조요법을 사용하는 것이 표준적인 치료방법이다. 1 표재성 방광암의 경우 치료 후에 45-70%가 재발하고 5-15%는 침윤성 암으로 진행한다. 2 표재성 방광암이 재발하는 이유로는 진단 당시에 종양의 다발성으로 발생하는 것, 불완전한 TURB, 발암물질의 지속 적 노출, 요상피세포가 종양세포로 분화하기 쉬운 환자의 특성, 방광 내시경 등과 같은 기구조작이나 다른 원인에 의 한 요로상피의 손상부위를 통한 종양세포의 파급 등이 있 다. 3-7 방광암의 공간 및 시간적 다발성 또는 재발성의 특징 을 설명하는 이론으로 'field change'와 'clonality' 이론이 제
시되지만 방광암의 다발성이나 재발에서 어떠한 역할을 하 는지는 아직 확실하지 않다. 8 
